2013-01-07 18:14:37 -

GHENT, Belgium, 7 January 2013 - Ablynx [Euronext Brussels: ABLX] today
announces it will present at the 31(st) Annual J.P. Morgan Healthcare Conference
in San Francisco, California on Thursday, 10(th) January 2013 at 12:00 p.m. PST
(21:00 p.m. CET).

The presentation, followed by a Q&A, will be hosted by Dr Edwin Moses, CEO and
Chairman of Ablynx. The presentation will provide an update on the Company's
late-stage proprietary Nanobody® programmes, the Company's growth and partnering
strategy and the outlook for the near term future.

The presentation will be webcast live and can be accessed on the day via the
Ablynx website at A replay of the webcast will be available on
the Company's website for 30 days following the presentation. To ensure a timely
connection, it is recommended that users register at least 10 minutes prior to
the scheduled webcast.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development
of Nanobodies(®), a novel class of therapeutic proteins based on single-domain
antibody fragments, for a range of serious human diseases, including
inflammation, haematology, oncology and pulmonary disease. Today, the Company
has approximately 25 programmes in the pipeline and five Nanobodies at clinical
development stage. Ablynx has ongoing research collaborations and significant
partnerships with major pharmaceutical companies including Boehringer Ingelheim,
Merck KGaA, Novartis and Merck & Co. The Company is headquartered in Ghent,

More information can be found on

For more information, please contact

Dr Edwin Moses
Chairman and CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
     +32 (0)473 39 50 68

Marieke Vermeersch
Associate Director Investor Relations
t:   +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
Follow us on Twitter @AblynxABLX

Mary-Jane Elliott, Amber Bielecka, Claire Dickinson
t:   +44 207 920 2330

press release in pdf format:

This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Ablynx via Thomson Reuters ONE

Press Information:

Contact Person:

email: e-mail

Disclaimer: © 2014 Thomson Reuters. The press releases or report contained herein is protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Thomson Reuters's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.